Education
About Us
Working with TipRanks
Follow Us
Verrica Pharmaceuticals (VRCA)
NASDAQ:VRCA
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 7.57M | $ 5.12M | $ 9.03M | $ 12.00M | $ 0.00 |
| Gross Profit | $ 4.83M | $ 4.38M | $ 8.31M | $ 11.53M | $ -229.00K |
| Operating Income | $ -65.92M | $ -65.76M | $ -21.30M | $ -30.91M | $ -40.18M |
| EBITDA | $ -65.90M | $ -62.20M | $ -21.60M | $ -30.31M | $ -39.43M |
| Net Income | $ -76.58M | $ -67.00M | $ -24.49M | $ -35.08M | $ -45.50M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 46.33M | $ 69.55M | $ 34.27M | $ 70.35M | $ 65.47M |
| Total Assets | $ 54.13M | $ 81.60M | $ 44.72M | $ 80.13M | $ 74.15M |
| Total Debt | $ 45.94M | $ 45.51M | $ 1.53M | $ 43.41M | $ 37.21M |
| Net Debt | $ -390.00K | $ -24.04M | $ -32.75M | $ 27.66M | $ 26.52M |
| Total Liabilities | $ 63.99M | $ 61.83M | $ 4.69M | $ 47.52M | $ 41.17M |
| Stockholders' Equity | $ -9.86M | $ 19.76M | $ 40.03M | $ 32.60M | $ 32.99M |
| Cash Flow | |||||
| Free Cash Flow | $ -60.95M | $ -38.94M | $ -18.95M | $ -28.46M | $ -31.68M |
| Operating Cash Flow | $ -60.93M | $ -38.58M | $ -18.65M | $ -27.58M | $ -30.21M |
| Investing Cash Flow | $ -19.00K | $ -362.00K | $ 54.04M | $ -998.00K | $ -3.58M |
| Financing Cash Flow | $ 37.73M | $ 74.21M | $ -16.87M | $ 33.65M | $ 35.23M |
Verrica Pharmaceuticals Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.